Six Cases of Lung Injury Following Anti-tumour Necrosis Factor Therapy for Inflammatory Bowel Disease

J Crohns Colitis. 2015 Nov;9(11):1053-7. doi: 10.1093/ecco-jcc/jjv135. Epub 2015 Jul 27.


Background and aims: Limited data are available regarding the pulmonary toxicity of anti-tumour necrosis factor (anti-TNF) therapy for inflammatory bowel disease (IBD).

Methods: We retrospectively searched the IBD registry of Asan Medical Center in order to identify patients with lung injury following anti-TNF therapy.

Results: Among 1002 patients who were treated using anti-TNF therapy, six cases (0.6%) of anti-TNF-induced lung injury (ATILI) were identified. ATILI was observed soon after the beginning of anti-TNF therapy (two to four doses of anti-TNF). All of these patients experienced improvements in their respiratory symptoms and radiographic findings once the anti-TNF therapy was discontinued. One patient who suffered ATILI following adalimumab was switched to subsequent infliximab and was without recurrence of ATILI.

Conclusion: Clinicians should be vigilant regarding the possibility of ATILI in IBD patients treated with anti-TNF agents.

Keywords: Anti-tumour necrosis factor; inflammatory bowel disease; safety.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab / adverse effects*
  • Adalimumab / therapeutic use
  • Adult
  • Aged
  • Female
  • Follow-Up Studies
  • Gastrointestinal Agents / adverse effects*
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Inflammatory Bowel Diseases / complications
  • Inflammatory Bowel Diseases / drug therapy*
  • Infliximab / adverse effects*
  • Infliximab / therapeutic use
  • Lung Injury / chemically induced*
  • Lung Injury / diagnosis
  • Male
  • Middle Aged
  • Retrospective Studies
  • Treatment Outcome


  • Gastrointestinal Agents
  • Infliximab
  • Adalimumab